Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2012 /
Treatment of ALK+ lung cancer with crizotinib, Profile 1007

28th Sep - 2nd Oct 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.10.12
Views: 5097
Rating:

Dr Alice Shaw – Massachusetts General Hospital, Boston, USA

Dr Alice Shaw talks to ecancer at the 2012 ESMO meeting in Vienna about a randomised phase III study comparing targeted therapy crizotinib with standard chemotherapy in cases of ALK+ lung cancer.

 

ALK+ lung cancer is defined by a genetic abnormality and is present in about 5% of the total lung cancer population. The trial looked to increase progression free survival; results confirmed with a 7.7 month average increase with crizotinib compared to 3 months with standard chemotherapy. 

 

The total response rate with crizotinib was 65.3 percent. Side effects that occurred were visual disturbance, nausea vomiting diarrhea, liver irritation, but all were at manageable levels.

 

Filming Supported by Amgen

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation